Mycosis Fungoides Clinical Trial
— CTCLOfficial title:
Feasibility Study to Determine Effectiveness of 3.75% Topical Imiquimod Cream and Topical Vanos (Fluocinonide) Cream 0.1% in the Treatment of Early Stage Cutaneous T-cell Lymphoma
NCT number | NCT02301494 |
Other study ID # | 48861 |
Secondary ID | |
Status | Withdrawn |
Phase | N/A |
First received | |
Last updated | |
Start date | April 2020 |
Est. completion date | April 2023 |
Verified date | April 2021 |
Source | Rochester General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is being conducted by Brian Poligone, MD PhD. The purpose of this study is to determine safety, effectiveness, and tolerability of two topical therapies, imiquimod and fluocinonide, for patients with early stage Cutaneous T-cell Lymphoma (CTCL).
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | April 2023 |
Est. primary completion date | April 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Male and female subjects aged =18 years. 2. Willing and able to give informed consent 3. Diagnosis of Mycosis Fungoides In cases with equivocal histological features, the diagnosis may be confirmed through the use of clonal T-cell gamma gene rearrangement, as detected by PCR amplification and primer sets specific for the T-cell receptor gamma chain genes. 4. Subjects must have at least one target lesion 5. Subjects will be able to comply with the study instructions, apply the study medication as directed and attend all visits. 6. Females of child-bearing potential must have a negative urine pregnancy test before randomization and must agree to use an adequate method of contraception (abstinence, condoms, hormonal therapy, barrier methods) during the study. 7. Patients must be otherwise healthy with an ECOG Performance status of 0 or 1. 8. The patient must not have had topical (2 weeks) or systemic therapy (4 weeks), radiotherapy (4 weeks) or phototherapy therapy (4 weeks) for Mycosis Fungoides within the stated number of weeks prior to start of treatment. 9. Eligible patients will be those who topical corticosteroid would be a preferred treatment and include patients newly diagnosed with stage IA, IB, or IIA disease, or those patients currently stable on therapy, in whom topical corticosteroids are being newly added to the regimen (i.e. recurrence or resistant lesions not currently treated with topical corticosteroids) Exclusion Criteria: To be eligible for inclusion in this study the subjects must not meet any of the following criteria: 1. Female who is pregnant, nursing an infant, or planning a pregnancy during the study period. 2. Have concomitant dermatologic or medical condition(s) which may interfere with the investigator's ability to evaluate the subject's response to the study drug. 3. Received any investigational drug or taking part in any clinical study within one month prior to this study. 4. Known reaction or allergy to test drug or excipient. 5. Presence of major medical illness or symptoms of a clinically significant illness that may influence the study. 6. Have any reason which, in the opinion of the investigator, interferes with the ability of the subject to participate in or complete the trial, or which places the subject at undue risk such as a history of drug, alcohol or other substance abuse or other factors limiting the ability to co-operate and to comply with this protocol. 7. Lesions on the genitals, axillae and face will not be selected for study treatment and evaluation. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Rochester General Hospital | Bausch Health Americas, Inc., Rochester Skin Lymphoma Medical Group, PLLC |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Response Rate between baseline and week 16 | Treatment phase will last 4 months with follow up at 6 and 12 months after initiation of therapy | 16 weeks | |
Secondary | Response Rate 24 and 52 weeks after baseline | Patients will be treated for 4 months and response rate assessed at 6 and 24 months after initiation of therapy. | Baseline to up to one year | |
Secondary | Safety and tolerabiliy of Imiquimod in patients with CTCL (adverse events) | We will record any adverse events that occur during the course of the study. | From Randomization to up to 30 days after end of treatment | |
Secondary | Learn about T cell dysregulation in the skin from patients with CTCL (Using left over tissue from biopsies) | Using left over tissue from biopsies done at baseline, two weeks after initiation of therapy, and optional one done at week16. We are interested in making our tissue bank. | Samples may be stored indefinitely from time of collection ( two weeks after initiation of therapy, and optional one done at week16) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02890368 -
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
|
Phase 1 | |
Not yet recruiting |
NCT02881749 -
Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides
|
Phase 2 | |
Completed |
NCT00051012 -
Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients
|
Phase 4 | |
Terminated |
NCT03789864 -
Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides
|
N/A | |
Completed |
NCT01590732 -
Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma
|
Phase 1 | |
Recruiting |
NCT02848274 -
ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
|
||
Recruiting |
NCT00177268 -
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
|
||
Recruiting |
NCT05357794 -
Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides
|
Phase 2 | |
Completed |
NCT04955340 -
A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat
|
Phase 1 | |
Recruiting |
NCT04960618 -
Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome
|
Phase 2 | |
Completed |
NCT02883517 -
Cell-free Circulating DNA in Primary Cutaneous Lymphomas
|
||
Active, not recruiting |
NCT02953301 -
Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)
|
Phase 2 | |
Completed |
NCT00254332 -
Effect of Denileukin Diftitox on Immune System in CTCL Patients
|
N/A | |
Completed |
NCT02296164 -
Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma
|
||
Recruiting |
NCT05680558 -
Photopheresis in Early-stage Mycosis Fungoides
|
Phase 2 | |
Completed |
NCT00038376 -
Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies
|
Phase 2 | |
Completed |
NCT00168064 -
Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides
|
Phase 2 | |
Recruiting |
NCT05879458 -
Ritlecitinib in CTCL
|
Phase 2 | |
Recruiting |
NCT05414500 -
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
|
Phase 1 | |
Recruiting |
NCT05904522 -
Histopathological Changes in Mycosis Fungoides
|
N/A |